Education
About Us
Working with TipRanks
Follow Us
Nectar Lifesciences Ltd. (IN:NECLIFE)
:NECLIFE
NECLIFE Stock Chart & Stats
₹18.25
-₹0.79(-2.00%)
At close: 4:00 PM EST
₹18.25
-₹0.79(-2.00%)
Day’s Range― - ―
52-Week Range₹11.60 - ₹29.95
Previous CloseN/A
Volume216.67K
Average Volume (3M)34.32K
Market Cap
₹2.61B
Enterprise Value₹7.13B
Total Cash (Recent Filing)₹197.51M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding224,260,970
10 Day Avg. Volume25,321
30 Day Avg. Volume34,323
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.56
Price to Sales (P/S)0.32
P/FCF Ratio4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical Business ModelNectar sells APIs, finished formulations and offers contract manufacturing, spreading revenue across product types and customer segments. That diversification supports resilience versus single-product exposure, helps optimize utilization, and preserves optionality to shift mix toward higher-margin or export contracts over months.
Moderate, Stable Capital StructureA moderate debt-to-equity and stable equity ratio indicate the company has maintained balanced leverage. This structural strength supports financial flexibility for working capital and targeted capex, reducing refinancing stress and enabling investment in quality/compliance that underpins long-term pharma manufacturing competitiveness.
Improving Operating Cash GenerationRecent improvement in operating cash flow signals the company can translate operations into cash, which is durable for funding working capital and incremental manufacturing investments. Even if volatile historically, an improving trend reduces short-term liquidity risk and supports sustaining operations during recovery phases.
Bears Say
Steep Revenue ContractionA greater-than-50% revenue decline is a structural risk: it compresses scale economies, lowers capacity utilization in manufacturing, and erodes bargaining power with suppliers and buyers. Persistent shrinkage would hamper margin recovery and make rebuilding export or contract volumes materially harder over months.
Negative Profitability And Margin ErosionSustained negative net margins and falling gross margins point to cost, pricing, or mix problems that weaken long-term earnings power. Margin deterioration reduces internal funds for reinvestment, constrains R&D/manufacturing upgrades and raises the likelihood that operational fixes will be required before profits normalize.
Earnings Volatility And EPS CollapseAn extreme negative EPS swing reflects one-off shocks or recurring losses and makes forecasting cash flows and capital needs difficult. Combined with inconsistent free cash flow history, such earnings volatility undermines creditor and customer confidence and limits the firm's ability to plan multi-month investments or secure favorable financing.
Nectar Lifesciences Ltd. News
NECLIFE FAQ
What was Nectar Lifesciences Ltd.’s price range in the past 12 months?
Nectar Lifesciences Ltd. lowest stock price was ₹11.60 and its highest was ₹29.95 in the past 12 months.
What is Nectar Lifesciences Ltd.’s market cap?
Nectar Lifesciences Ltd.’s market cap is ₹2.61B.
When is Nectar Lifesciences Ltd.’s upcoming earnings report date?
Nectar Lifesciences Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 92 days.
How were Nectar Lifesciences Ltd.’s earnings last quarter?
Nectar Lifesciences Ltd. released its earnings results on Jan 23, 2026. The company reported ₹0.636 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.636.
Is Nectar Lifesciences Ltd. overvalued?
According to Wall Street analysts Nectar Lifesciences Ltd.’s price is currently Overvalued.
Does Nectar Lifesciences Ltd. pay dividends?
Nectar Lifesciences Ltd. pays a Annually dividend of ₹4.319 which represents an annual dividend yield of N/A. See more information on Nectar Lifesciences Ltd. dividends here
What is Nectar Lifesciences Ltd.’s EPS estimate?
Nectar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nectar Lifesciences Ltd. have?
Nectar Lifesciences Ltd. has 224,260,970 shares outstanding.
What happened to Nectar Lifesciences Ltd.’s price movement after its last earnings report?
Nectar Lifesciences Ltd. reported an EPS of ₹0.636 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.549%.
Which hedge fund is a major shareholder of Nectar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in IN:NECLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nectar Lifesciences Ltd.
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Medicamen Biotech Limited
―
Sakar Healthcare Ltd
―
Venus Remedies Limited
―
Zim Laboratories Ltd.
―